Cannell & Spears’s Vertex Pharmaceuticals VRTX Stock Holding History

Cannell & Spears’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$885K	Buy	1,983 +23	+1%	+$10.7K	0.02%	250
2025 Q4	$889K	Hold	1,960	–	–	0.02%	249
2025 Q3	$768K	Buy	1,960 +88	+5%	+$36.8K	0.01%	255
2025 Q2	$833K	Sell	1,872 -37	-2%	-$17.1K	0.02%	242
2025 Q1	$926K	Sell	1,909 -32	-2%	-$14.9K	0.02%	229
2024 Q4	$782K	Buy	1,941 +3	+0.2%	+$1.39K	0.02%	255
2024 Q3	$901K	Sell	1,938 -209	-10%	-$100K	0.02%	249
2024 Q2	$1.01M	Sell	2,147 -380	-15%	-$165K	0.02%	221
2024 Q1	$1.06M	Buy	+2,527	New	+$1.07M	0.02%	222

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cannell & Spears's VRTX Position: Q1 2026 in Review

Cannell & Spears increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q1 2026, buying an estimated $10.7K and bringing the position to 1,983 shares worth $885K. The position accounts for 0.02% of the portfolio, ranked #250.

Cannell & Spears first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.06M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Cannell & Spears held 1,983 shares of Vertex Pharmaceuticals worth $885K as of Q1 2026.
Cannell & Spears bought 23 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.7K.
Vertex Pharmaceuticals made up 0.02% of Cannell & Spears's portfolio in Q1 2026, its #250 holding.
Cannell & Spears first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Cannell & Spears's Vertex Pharmaceuticals position peaked at $1.06M in Q1 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.